JRCT ID: jRCT1050220135
Registered date:16/12/2022
A multicentre observational study of changes in clinical factors associated with the administration of immune checkpoint inhibitors in gastrointestinal cancer
Basic Information
| Recruitment status | Recruiting |
|---|---|
| Health condition(s) or Problem(s) studied | gastric cancer, oesophageal cancer |
| Date of first enrollment | 16/12/2022 |
| Target sample size | 280 |
| Countries of recruitment | |
| Study type | Observational |
| Intervention(s) |
Outcome(s)
| Primary Outcome | Progression free survival, Overall survival |
|---|---|
| Secondary Outcome |
Key inclusion & exclusion criteria
| Age minimum | >= 20age old |
|---|---|
| Age maximum | Not applicable |
| Gender | Both |
| Include criteria | Cases used Nivolumab/Pembrolizumab for unresectable or recurrent gastric and oesophageal cancer from October 2017 to December 2024 |
| Exclude criteria | Cases in which treatment was terminated before the start of the second course Cases where blood tests were not done before the start of the second course |
Related Information
| Primary Sponsor | Inatomi Osamu |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | |
| Secondary ID(s) |
Contact
| Public contact | |
| Name | Hiroto Inoue |
| Address | Shiga-Ken Otu city Seta Tukinowa-tyo Shiga Japan 520-2192 |
| Telephone | +81-77-548-2217 |
| inohiro@belle.shiga-med.ac.jp | |
| Affiliation | Shiga University of Medical Science |
| Scientific contact | |
| Name | Osamu Inatomi |
| Address | Shiga-Ken Otu city Seta Tukinowa-tyo Shiga Japan 520-2192 |
| Telephone | +81-77-548-2217 |
| osam@belle.shiga-med.ac.jp | |
| Affiliation | Shiga University of Medical Science |